Editor The failure early this month of Ribozyme Pharmaceuticals Inc.'s Angiozyme in a Phase II trial as a monotherapy against Stage IV metastatic breast cancer was enough to feed another round in the sporadic, ongoing debate over angiogenesis inhibitors. Can they work? Is it worth trying to "turn off" blood vessel growth for the purpose of starving tumors (as in Ribozyme's case), or trying to "turn on" their growth as a treatment for heart diseases and others? A healthy body keeps its natural

Money Raised Year To Date

Company* (Country; Symbol) Product Description Indication Status (Date) AUTOIMMUNE Cambridge Antibody Technology Group plc (UK; CATG; LSE:CAT) and Abbott Laboratories Inc. D2E7 Monoclonal antibody; adalimumab Rheumatoid arthritis CAT and Abbott submitted D2E7 for approval in the U.S. and and Europe (4/17**) XOMA Ltd. (XOMA) and Genentech Inc. (NYSE:DNA) Xanelim Efalizumab; humanized antibody Psoriasis Companies said an FDA-requested pharmacokinetic study comparing XOMA-produced

Company* (Country; Symbol) Product Description Indication Status (Date) CANCER Atrix Laboratories Inc. (ATRX) and MediGene AG (Germany; Neuer Markt:MDG) Eligard (FDA- approved) 22.5-mg three-month depot; leuprolide acetate Prostate cancer MediGene submitted for approval in Germany (4/25) British Biotech plc (UK; BBIOY) E21R A granulocyte macrophage-colony stimulating factor antagonist Juvenile myelo- monocytic leukemia Drug was designated an orphan medicinal product in Europe (4/4

Company* (Country; Symbol) Product Description Indication Status (Date) AUTOIMMUNE AtheroGenics Inc. (AGIX) AGIX-4207 An intravenous compound derived from the v-protectant technology platform Rheumatoid arthritis Company completed a Phase I trial showing it was well tolerated (4/16) Centocor Inc. (subsidiary of Johnson & Johnson) Remicade (FDA- approved) Infliximab; a monoclonal antibody that specifically targets and irreversibly binds to TNF-alpha on the cell membrane in

Money Raised Year to Date

I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $406M Company Location Date Amt. (M) Details Apovia AG Martinsried, Germany 4/22 EUR19 (US$17.1) Apovia raised US$17.1M in a third-round funding led by Heidelberg Innovation; other investors were Genavent, Societe Generale Asset Management, VCH Equity Group AG, 3i, Global Life Science Holding II GmbH, Oxford Bioscience Partners and private individuals; Arthur Andersen Corporate Finance acted as adviser Axovan AG Basel, Switzerland 4/22 CHF30

Total: $1,045.1M Company (Symbol)# Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (M) Investors; Placement Agents; Details (Date)@ AEterna Laboratories Inc. (AELA; TSE:AEL) Private placement of common stock and warrants 7.57S and 7.43W C$57 (US$35.7) AEterna raised US$35.7M in two private placements, one with SGF Sante and Solidarity Fund QFL, and the other with Acqua Wellington Private Placement Fund Ltd.; the first one involved 7.3M shares and 7.3M warrants

I. COMMENCED TRADING IN APRIL Company (Symbol)# Date Filed Date Comm. Shares/Units (M) Price Shares Out (M)% Lead, Other Underwriters Gross (M) Post-Offering Market Cap (M)@ INITIAL OFFERINGS DOV Pharmaceutical Inc. (DOVP)1 1/28/02 4/25/02 5S $13 15 Lehman Brothers (co-lead) CIBC World Markets (co-lead) Lazard Freres Fidelity Capital Markets $65 $195 Ribapharm Inc. (NYSE:RNA)2 6/15/00 4/12/02 26S $10 150 UBS Warburg CIBC World Markets SG Cowen $260 $1,500 Total: $325M Number of

Editor Erectile dysfunction (ED) used to be called impotence, until doctors decided on what the Merck Manual of Diagnosis and Therapy refers to as a "less pejorative" and more specific phrase. But a rose by any other name smells the same ­ and this one stinks, for 10 million to 20 million men over age 18 afflicted with the condition in the U.S. The common form of ED (which some persist in calling "male erectile dysfunction") is secondary, notes the Merck handbook. This means the loss of a

Money Raised Year To Date

I. COMPLETED MERGERS AND ACQUISITIONS Company Acquired* (Country; Symbol) Acquired By Or Merged With* (Country; Symbol) Date Announced Date Completed Value (M)*** Terms/Details Apothogen Inc.* IntraBiotics Pharmaceuticals Inc. (IBPI) 4/25 4/25 $1.8 IntraBiotics acquired Apothogen for about 450,000 shares of stock, or $1.8M BioDisplay Technologies Inc.* Abbott Laboratories Inc. (NYSE:ABT) 4/1 4/1 $7 Abbott acquired the virtual company BioDisplay Technologies Inc. for

Editor As if implications of the Enron Corp. situation hadn't already messed things up enough for biotechnology (and just about every other sector that uses balance sheets and ledgers), another spawn of the scandal has reared its head for industry leaders to fear and loathe. Several spawns, actually. They come in the form of legislation in the House and in the Senate, and moves by the Internal Revenue Service and Financial Accounting Standards Board to change the guidelines for reporting

Money Raised Year To Date

I. MODIFIED AGREEMENTS Biotech Co.* (Country; Symbol) Pharma Co. (Country) Change from original agreement Terms/Details (Date) Applied Molecular Evolution Inc. (AMEV) Eli Lilly and Co. Agreement to optimize an additional antibody candidate The companies announced the initial collaboration in December for an antibody and a nonantibody protein; Applied Molecular will receive program funding and could receive additional milestone payments and royalties (2/21) Coley Pharmaceutical